Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis
Key facts
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 130 people, planned
- Started
- 1 Jan 2020
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lactoferrin + Iron Supplement
- Iron Supplement
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Age 18-75 years
- Either gender
- Patients with chronic liver disease with iron deficiency anemia with transferrin saturation<20% and Hemoglobin in Non-pregnant women (15 years of age and above) <12g/dl and in men <13g/dl -
Who cannot take part
- Post liver transplant patients
- Patients who are on psychoactive drugs, like sedatives or antidepressants
- Severe preexisting cardiopulmonary disease
- HIV infection
- Renal dysfunction (S. Creatinine ≥ 2mg/dL)
- Those who do not consent to participate in the study
- Inability to obtain informed consent from patient or relatives
- Pregnancy/Lactation
- Patients who are too sick to carry out the protocol
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization are main factors involved in anemia in liver disease. Lactoferrin is a first line defence protein for protection against microbial infections and subsequent development of systemic disease as seen with systemic inflammatory response syndrome (SIRS) and sepsis. Lactoferrin with iron has been shown to be efficacious with anemia in chronic disease, in pregnancy and in cancer patients with fewer side effects than oral iron alone. High exposure to iron is associated with increased inflammation which is associated with worse cardiovascular outcomes. Lactoferrin can help reduce the total iron dose and hepatic inflammation.
The 2 groups in the trial
- Group A: Lactoferrin plus oral ironTreatment being tested
Treated for 2 months regularly with oral administration of 100 mg Lactoferrin tablet twice a day before meals with oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
Treatment: Lactoferrin + Iron Supplement
- Oral iron aloneExisting treatment, for comparison
Oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
Treatment: Iron Supplement
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Lactoferrin With Iron Versus Iron Alone in Treatment of Anemia In Chronic Liver Disease
- Record updated
- 13 November 2026